Abbott Laboratories vs. Intuitive Surgical: Recent Quarterly Revenue Trends Reveal a Classic Investing Truth

Abbott Laboratories: Maintaining Steady Baseline Revenue Growth

Abbott Laboratories (NYSE:ABT) primarily generates its revenue by researching, developing, manufacturing, and distributing a diverse portfolio of medical devices, diagnostic test systems, nutritional formulas, and generic pharmaceutical products across international healthcare networks.

Recently, it entered a global licensing agreement with ALZpath to advance blood-based disease testing and reached administrative agreements to resolve specific infant formula litigation claims. It reported an operating margin of approximately 14% for the quarter ended June 30, 2026.

Intuitive Surgical: Scaling Up Core Surgical Revenue

Intuitive Surgical (NASDAQ:ISRG) primarily earns its revenue by manufacturing and selling robotic-assisted surgical systems, alongside the specialized disposable medical instruments, digital diagnostic accessories, and extensive technical training services required for medical facilities to operate them.

While managing regulatory product recalls involving specific surgical instrument components and observing cooled domestic medical procedure volume trends, it established a new patient awareness campaign and recorded an operating margin of about 34% for the quarter ended June 30, 2026.

Why the Top-Line Revenue Metric Matters for Retail Investors

Revenue here refers to the data provider's standardized income-statement revenue line item, and tracking this particular financial metric helps individual retail investors understand the actual total amount of money a business brings in before any associated operational expenses are subtracted.

Comparing Quarterly Revenue for Abbott Laboratories and Intuitive Surgical

Data source: Company filings. Data as of Sept. 11, 2026.

Foolish Take

Comparing the recent revenue trends between Abbott Labs and Intuitive Surgical brings up a truth many investors know well: As companies get larger, their growth rates tend to slow down. For a high-quality company, the trade-off is stability, as well as other perks, like Abbott's 2.5% dividend yield (Intuitive doesn't pay a dividend).

Abbott Laboratories is working off a $10 billion lead over Intuitive Surgical's total revenue count, but Intuitive's revenue grew by 45% from Q3 2024 to Q2 2026, trouncing Abbott's 19% growth. That also means, despite Intuitive's impressive growth, Abbott added $2 billion to its top line in the time frame above, versus Intuitive's less than $1 billion gain.

Both companies appear to have solid business models, recurring revenue streams, and future growth opportunities, but their growth paths may look different from here. Investors should watch to see if Intuitive can continue adding revenue at its current pace, or if it begins to plateau. The March-ending quarter also appears to be seasonally weak for both companies. A correction here could be worth noting.

Both stocks have suffered recently. Abbott is down 17.6% on a total return basis over the time period above, while Intuitive is down 19%, with both experiencing steep losses this year. With more research, you may find that one or both of these healthcare companies present an attractive entry point right now.

Sarah Sidlow has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Intuitive Surgical. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.